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Abstract
Rationale Experienced cannabis users demonstrate tolerance
to some of the impairing acute effects of cannabis.
Objectives The present study investigates whether event-
related potentials (ERPs) differ between occasional and
heavy cannabis users after acute Δ
9-tetrahydrocannabinol
(THC) administration, as a result of tolerance.
Methods Twelve occasional and 12 heavy cannabis users
participated in a double-blind, placebo-controlled, cross-
over study. On two separate days, they smoked a joint
containing 0 or 500 μg/kg body weight THC. ERPs were
measured while subjects performed a divided attention task
(DAT) and stop signal task (SST).
Results In the DAT, THC significantly decreased P100
amplitude in occasional but not in heavy cannabis users.
P300 amplitude in the DAT was significantly decreased by
THC in both groups. The N200 peak in the SST was not
affected by treatment in neither of the groups. Performance
in the SST was impaired in both groups after THC
treatment, whereas performance in the DAT was impaired
by THC only in the occasional users group.
Conclusions The present study confirms that heavy canna-
bis users develop tolerance to some of the impairing
behavioral effects of cannabis. This tolerance was also
evident in the underlying ERPs, suggesting that tolerance
demonstrated on performance level is not (completely) due
to behavioral compensation.
Keywords Cannabinoids.Cognition.Psychomotor
performance.Event-related potentials.Tolerance
CannabisisthemostfrequentlyusedillicitdrugintheWestern
world, with estimates going up to 18% of Europeans having
tried cannabis at least once in their life (Rigter and van Laar
2002). The widespread use of cannabis and its potential for
increased therapeutic use have given rise to significant public
health concern, mostly regarding the effects of cannabis on
cognition and psychomotor function.
The acute effects of Δ
9-tetrahydrocannabinol (THC), the
major psychotropic compound in cannabis, on cognitive
and psychomotor performance have been assessed in
numerous experimental studies using within-subject,
double-blind, placebo-controlled designs. These have gen-
erally shown that THC in doses between 40 and 300 μg/kg
causes a dose-dependent reduction in performance at tests
measuring memory, attention, reaction time (RT), tracking,
and motor function (Curran et al. 2002; Hall and Solowij
1998; Heishman et al. 1997). This performance impairment
after acute THC administration was shown to be highest
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DOI 10.1007/s00213-011-2479-xduring the first hour after smoking or between 1 and 2 h
after oral intake (Curran et al. 2002). The number of
significant performance effects sharply declined to about
zero over 3–4 h after THC use.
It has been demonstrated that frequency and history of
cannabis use can affect the performance outcome. In a
study by Pope and Yurgelun-Todd (1996), heavy cannabis
users (smoking approximately daily) showed significantly
greater impairment than light users (smoking on average
once a month) on attentional and executive functions after a
minimum of 19 h abstinence. In another study by Pope et
al. (2001), current heavy users (smoked >5,000 times and
smoking daily) demonstrated cognitive impairment up to
7 days after last cannabis use. This impairment was related
to levels of carboxy-THC in urine and was no longer
present after 28 days of abstinence. Bolla et al. (2002) did
demonstrate impairment after 28 days of abstinence in very
heavy cannabis users (smoking approximately 35 joints/
week), but found no relation with duration of use. In a
longitudinal study, Fried et al. (2002) compared IQ scores
of light (<5 joints/week) and heavy (≥5 joints/week) current
users, former users, and nonusers. These IQ scores were
compared with the subjects’ IQ scores that were obtained
before initiation of drug use. Fried et al. (2002) found that
current marijuana users showed a lower overall IQ, but only
in the heavy users group. The former heavy users, who had
not used in at least 3 months, showed no decline in IQ
score. Therefore, it can be concluded that impairment is
apparent in current regular users, even when they are not in
an intoxicated state, but that this impairment is not
permanent if they stop using (Fried et al. 2002).
From these studies, it can be concluded that cognitive
impairments can be demonstrated in cannabis users up to a
couple of days after their last use and that this impairment
is related to the duration and frequency of use. However,
none of these studies have looked at the effect of frequency
or duration of use on the acute effects of cannabis.
As with other drugs, regular cannabis use induces
tolerance for the acute effects. Previous studies have
demonstrated that frequent use of low doses of cannabis
can rapidly induce tolerance for the subjective high of
cannabis (Cappell and Pliner 1974; Jones et al. 1981). Hart
et al. (2001) also demonstrated that heavy cannabis users
showed only minimal impairment on complex cognitive
tasks after acute cannabis administration. However, it is
hard to draw conclusions from this study, as an infrequent
cannabis user group was not included. Furthermore, the
lack of impairment may be due to the fact that subjects
were still impaired in the placebo condition as a result of
residual effects. In addition, the exact dose of administered
THC was not reported, nor were plasma THC concen-
trations provided (Nordstrom and Hart 2006; Ramaekers et
al. 2006).
We recently investigated neurocognitive performance in
heavy (using cannabis >4 times/week) and occasional
cannabis users (using cannabis <2 times/week) during acute
intoxication (Ramaekers et al. 2009). In this placebo-
controlled study, a high dose of THC (500 μg/kg) was
administered, while performance measures were conducted
four times between 0 and 8 h after smoking. This study
demonstrated that the acute effect of THC on human
performance is dependent on cannabis use history. Occa-
sional users showed impairments in all performance tasks
(i.e., tracking, divided attention task [DAT], and stop signal
task [SST]) after smoking cannabis. Heavy users only
demonstrated impairment in one performance parameter
(i.e., impulse control as measured in the SST) and only at
THC concentration above 10 ng/ml in serum. This suggests
that heavy cannabis users develop tolerance for some of the
impairing effects of cannabis. While this may be the result
of pharmacological adaptations, it may also be due to
behavioral compensatory mechanisms. Therefore, the be-
havioral performance of subjects might not be a good
indicator for the effect of drugs on brain functioning.
Previous studies, using positron emission tomography and
functional magnetic resonance imaging, have demonstrated
differences in brain activity in heavy current users and 25-day
abstinent heavy users, despite a lack of performance differ-
ences (Eldreth et al. 2004;K a n a y a m ae ta l .2004). These
studies suggest that experienced abstinent users draw on
alternative neural networks in order to compensate for the
impairment caused by THC.
Event-related potentials (ERPs) are well suited to
investigate brain functioning directly. Few studies have
examined the effects of cannabis on ERP measures. A
consistent finding in those ERP studies is that P300
amplitude is decreased in acutely intoxicated cannabis
users (Böcker et al. 2010; Ilan et al. 2004, 2005; Roser et
al. 2008) and in cannabis users who are not under the
influence of the drug at that time (Kempel et al. 2003;
Solowij et al. 1991). The P300 component has previously
been shown to reflect attentional resource allocation and
working memory (Kok 2001; Polich and Kok 1995). ERPs
after acute THC administration are even scarcer. In a single
case study, Solowij et al. (1995) showed that acute THC
administration after 6 weeks of abstinence normalized the
ERP (processing negativity) of a heavy cannabis user
during selective attention.
The aim of the present study is to assess ERP measures
during THC intoxication in occasional and heavy cannabis
users. This will elucidate whether tolerance to the impairing
effects of THC can be demonstrated at the neurophysio-
logical level, as has been shown at the behavioral level in
heavy cannabis users. This study was part of a larger study
of which the results are already published (Ramaekers et al.
2009) and involves the same subjects.
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Subjects
All participants were used to smoking cannabis in combi-
nation with tobacco. Twelve occasional cannabis users
[8 males and 4 females; mean age 22.8 years (±2.3)] and 12
heavy users [9 males and 3 females; mean age 23.2 years
(±3.3)] were included in this study. A summary of the
participants’ demographics and drug use characteristic is
given in Table 1. Independent-samples t tests showed that
there were no differences between groups, except of course
on cannabis use per year.
Subjects were recruited through advertisements in coffee
shops and at the university site. A first screening consisted
of a medical and drug questionnaire. Heavy users were
selected when smoking more than four times a week, while
the occasional group consisted of users that smoked less
than twice a week. Selected subjects were subsequently
examined by a medical supervisor who checked vital signs
and took blood and urine samples. Standard blood
chemistry, hematology, and drug screen tests were per-
formed on these samples. Inclusion criteria were free from
psychotropic medication; good physical health as deter-
mined by the medical examination and laboratory analysis;
absence of any major medical, endocrine, and neurological
condition; body mass index between 18 and 28 kg/m
2; and
written informed consent. Exclusion criteria were any
history of drug abuse or addiction (other than cannabis);
pregnancy or lactation or failure to use reliable contracep-
tive; excessive drinking (>20 alcoholic consumptions a
week); excessive smoking (>25 cigarettes/day); hyperten-
sion (diastolic >100; systolic >170); presence or history of
a psychiatric illness; color blindness; or dyslexia.
The study was approved by the Ethics Committee of
Maastricht University Hospital and conducted according to
the World Medical Associations Declaration of Helsinki
(Edinburgh modification 2000). A permit for obtaining,
storing, and administering marijuana was obtained from the
Dutch drug enforcement administration. All subjects received
financial compensation for their participation.
Design, doses, and administration
The study was conducted according to a double-blind,
placebo-controlled, two-way crossover design. Subjects
received placebo and 500 μg/kg body weight THC on
two separate test days. Subjects were told that they would
receive different doses of THC on separate test days. There
was a minimum period of 7 days between treatments.
S m o k i n go c c u r r e di nt h em o r n i n go ft e s td a y s .T h e
cigarettes were prepared beforehand for each individual.
Cannabis stock was provided by the Dutch Bureau for
Medicinal Cannabis and contained 13% THC. The total
weight of the cigarette was 0.8 g, containing tobacco and
500 μg/kg body weight THC. This lead to an average
cannabis content of 0.256 g for the heavy users group and
0.277 g for the occasional users group. Placebo cigarettes
contained 0.8 g of tobacco. Participants were instructed to
smoke the cigarette according to a fixed procedure in order
to minimize the subject’s possibility of dose titration and to
increase optimal absorption of THC (Robbe 1994), i.e.,
inhale for 4 s, hold breath for 10 s, and exhale/brake for
15 s. This was repeated until the cigarettes were smoked as
Table 1 Subject demographics (mean, SD) and history of drug use in heavy and occasional cannabis users
Heavy Occasional
N 12 12
Age (years) 23.2 (3.3) 22.8 (2.3)
Weight (kg) 66.6 (8.4) 71.9 (16.6)
Cannabis use (times)/year 340 (86) 55 (36)
Joints per occasion 2.3 (1.2) 1.2 (0.5)
Years of cannabis use 6.2 (3.4) 7.4 (2.7)
Alcoholic drinks/week 7.4 (7.4) 8.5 (6.6)
Number of regular tobacco users 8 6
Mean number cigarettes/day 6.25 (4.3) 6.17 (6.6)
Number of subjects having used During previous year Mean frequency of use
in previous year
During previous year Mean frequency of use
in previous year
Ecstasy 5 2 4 4 2 1.5
Amphetamine 2 0 2 1 1
Cocaine 4 3 1.7 2 1 1
Mushrooms 4 1 1 7 2 1.5
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number of puffs smoked from the placebo and THC
cigarette was 25 (6.4) and 28 (15.4) for the occasional
users and 22 (7.5) and 22 (8.2) for the heavy users,
respectively.
Procedures
All participants were asked to refrain from any drug (except
cannabis) use during the entire study. The occasional users
were asked not to use cannabis for a minimum of 5 days
prior to each test day, while the heavy users were to
continue using cannabis according to their normal routine.
Alcohol was not allowed 24 h prior to each test day and
caffeine was not allowed on a test day. Participants were
asked to arrive at the site well rested. Drug screens (Mahsan
Kombi DOA6+ urine drug test) and alcohol breath analyses
were performed upon arrival of the subjects, screening for
the presence of alcohol, THC, opiates, amphetamine,
cocaine, methamphetamine, and benzodiazepines. For
occasional users, administration of the placebo or THC
cigarette was only continued if drug and alcohol tests were
negative. In case of a positive drug test, subjects were sent
home and their test day was rescheduled. For the heavy
users, administration of the cigarette (THC or placebo) was
only continued if they were positive for THC, but negative
for other drugs and alcohol.
Prior to the first test session, subjects received training in
order to familiarize them with the tests and procedures and
minimize practice effects. On test days, subjects received a
standard breakfast prior to smoking. The performance tasks
and ERP registration began 20 min after smoking.
ERP measures during task performance
An electro-cap with 30 tin electrodes was used to record
EEG activity (standard 10–20 system; Fz, Cz, Pz, Oz, F3,
F4, F7, F8, C3, C4, T3, T4, T5, T6, P3, P4, O1, O2, Fp1,
Fp2, Ft7, Ft8, Fc3, Fc4, Tp7, Tp8, Cp3, Cp4, FCz, CPz).
Electrodes were filled with electro-gel. All electrodes were
referenced to the left mastoid; FPz was used as ground
electrode. Horizontal EOG was recorded using electrodes
attached to the outer canthi of the eyes, while vertical EOG
was recorded from infraorbital and supraorbital electrodes
placed in line with the pupil of the left eye. All electrode
impedances were kept below 5 kΩ. ERPs were collected
using the Neuroscan 4.3 software, and SynAmps amplifiers
were used. All signals were continuously sampled at a rate
of 1,000 Hz and digitally filtered online with a high-pass
filter of 0.10 Hz and a low-pass filter of 100 Hz. Offline
continuous signals were epoched into 1,200 ms sweeps
including a 200-ms prestimulus baseline. All of the
sampled EEG and EOG epochs were baseline corrected
and filtered offline using a 30-Hz, 12 dB/oct digital low-
pass filter. EEGs were corrected for horizontal and vertical
eye movements according to a procedure by Semlitsch et al.
(1986). Sweeps containing an artifact exceeding +75 or
−75 μV were rejected.
Performance tasks
Divided attention task The DAT measures the ability to
divide attention between two tasks performed simulta-
neously (Moskowitz 1973). The primary task measures
the subjects’ ability to control a displayed error signal in a
first-order compensatory tracking task. Error is displayed as
a horizontal deviation of a cursor from the midpoint on a
horizontal, linear scale. Compensatory joystick movements
null the error by returning the cursor to the midpoint. The
difficulty of the task is set at a constant level of 50% of the
subjects’ maximum capacity, as determined in the training
session. Tracking error is measured as the difference in
millimeters between the average position of the cursor and
the middle of the horizontal scale. In the secondary task,
subjects monitor a central display upon which single digits
are presented at 1–2 s intervals. The occurrence of the digit
“2” is a signal for the subject to remove the foot from a
pedal as rapidly as possible. In total, 75 targets and 375
nontargets were presented. Mean absolute tracking error (in
millimeters)and numberofcontrol lossesare the performance
measures of the primary task. Number of correct detections
and average RT (in milliseconds) are the dependent variables
of the secondary task.
In the DAT, two ERP components were calculated, i.e.,
P100 and P300 (or P3b). P100 reflects early attentional
processes and appears around 100 ms above the visual
cortex (Mangun 1995; Mangun and Hillyard 1990). The
P300, or P3b, has mostly been demonstrated in oddball
tasks and appears between 300 and 800 ms in the parietal
area (Polich and Kok 1995). It reflects attentional resource
allocation and working memory and is affected by the
probability of the rare stimulus in both passive and active
tasks (Duncan-Johnson 1981; Mertens and Polich 1997;
Polich and Kok 1995). The P300 component has also been
shown to be an indicator for processing capacity in dual
tasks (Brocke et al. 1996; Duncan-Johnson 1981; Isreal et
al. 1980; Kok 2001; Smulders et al. 1995; Theunissen et al.
2004; Wickens et al. 1983).
In the present study, ERP averages for individual
subjects were calculated for correct responses to targets
and distracters of the secondary task of the DAT. Parietal
(Pz) P300 peak amplitude and latency were determined in a
window between 275 and 650 ms as a measure of the
amount of invested capacity in the secondary task.
Furthermore, the maximum P100 amplitude and latency at
Oz were scored between 80 and 200 ms to examine the
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of stimuli in the secondary task.
Stop signal task The SST measures motor impulsivity,
which is defined as the inability to inhibit a precued
response. The current test was adapted from an earlier
version of Fillmore et al. (2002). In this task, subjects are
required to make quick key responses to visually presented
go signals and to inhibit any response when a visual stop
signal is suddenly presented. The go signals were four 1.5-
cm letters (ABCD) presented one at a time in the center of a
computer screen. Subjects were required to respond to each
letter as quickly as possible by pressing one of two
response buttons. One button is pressed to indicate that
“A” or “C” appeared and the other to indicate that “B” or
“D” appeared. Letters are displayed for 500 ms and the
computer screen was blank for 1.5 s interstimulus interval
before the next letter was displayed. The test consisted of
192 trials in which each of the 4 letters were presented
equally often. The stop signal occurred in half of the trials
and consisted of a visual cue, i.e., “*”, that appeared in one
of the four corners of the screen. Subjects were required to
withhold any response in case a stop signal was presented.
Stop signals were presented 24 times at each of the 4 delays
after the onset of a letter: 50, 150, 250, and 350 ms. Trials
always began with a 500-ms preparation interval in which a
fixation point appeared on the center of the screen.
Dependent variables are stop RT and response accuracy.
Stop RT is calculated by subtracting the stop signal delay
from the RT on go trials associated with n-th percentile of
the RT distribution. The n-th percentile corresponds to the
percentage of commission errors (not inhibited in stop trial;
Logan 1994).
In the SST, the N200 was measured. The negative N200
peak occurs around 200 ms post-stimulus, predominantly in
frontal areas, and is reported to be related to response
inhibition (Falkenstein et al. 1999; Jodo and Kayama
1992). The N200 amplitude and latency were measured at
Fz for correct responses to go trials and for correct
inhibitions to the stop signal (four stop signal delays
separately), as the minimal amplitude between 150 and
300 ms after the onset of the go signal or each stop signal.
As the N200 is an indication of response inhibition, it is
expected to be larger in stop conditions.
Subjective high
Directly after smoking and at 45 min post-smoking, a visual
analog scale (100 mm) was used by the subject to rate their
feeling of “high” as a percentage of the maximum ever
experienced (0 indicating not high at all, 100 meaning
maximally high).
Pharmacokinetic assessments
Blood samples (6 ml) were taken by venipuncture at
baseline, immediately after smoking, and every 15 min
during the first hour after smoking. Samples were centri-
fuged after 30 min and the serum was frozen at −20°C until
analyses for pharmacokinetic assessments. THC, THC-
COOH, and OH-THC concentrations were determined
using solid-phase extraction and gas chromatography with
mass spectrometric detection with a limit of quantification
of 0.5 ng/ml (for a more detailed description of the method,
see Toennes et al. 2010).
Data analyses
Behavioral data were analyzed with a univariate ANOVA
with the factors THC (two levels) and cannabis use history
(two levels) and their interaction. All ERP parameters were
normally distributed and analyzed using ANOVA with the
within-subject factors THC (two levels) and stimulus (two
levels for DAT and five levels for SST) and the between-
subject factor cannabis use history (two levels) and their
interactions. All variables were tested two-tailed with a
significance level p<0.05. A Pearson correlation was used
to test the relation between behavioral measures, ERP
measures, and THC concentrations. All statistical tests were
conducted using SPSS (version 15).
Results
Missing data
Due to technical problems, one subject’sf o o tr e s p o n s e s
(secondary task) were not registered during the DAT in the
THC condition. One subject was not able to inhibit his
responses in the SST; therefore, no ERPs could be calculated
for this subject (occasional user in the THC condition). ERPs
of the SSTare also missing for one subject (heavy user in the
THC condition), while ERP DAT data from three subjects
(one heavy user and two occasional users; all in the THC
condition) are missing due to technical malfunctioning.
Subjective high
Mean (SE) values for the subjective high for both groups
and treatments are shown in Table 2. In both groups,
subjective high was significantly increased immediately
and 45 min after smoking THC (F1,44=47.08, p<0.000 and
F1,43=44.81, p<0.000, respectively). Immediately after
smoking, subjective high ratings were also larger in the
occasional users compared to heavy users in both THC and
placebo condition (F1,44=7.13, p=0.011).
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THC concentrations in serum were overall higher in heavy
users compared to occasional users. Occasional users were
negative for THC in the placebo condition, whereas heavy
users were positive in the placebo condition and at baseline.
A summary of the mean (SD) THC, THC-COOH, and OH-
THC is given in Table 3.
Divided attention task
Mean (SE) values for performance on the DAT are given in
Table 2. Behavioral measures of the DAT were significantly
influenced by THC. THC increased the number of control
losses (F1,44=5.812, p=0.02) and RT (F1,43=5.724, p=
0.021) and decreased number of hits (F1,43=5.026, p=
0.03). These effects were specific for the occasional users
as indicated by a significant or nearly significant THC×
cannabis use history interaction for the number of control
losses (F1,44=4.900, p=0.032), RT (F1,43=3.945, p=
0.053), and number of hits (F1,43=4.425, p=0.042).
P100 E R Pa n a l y s i si n c l u d e d1 1h e a v yu s e r sa n d1 0
occasional users in the THC condition and all subjects in
the placebo condition. Mean (SE) values of the ERPs from
the DAT are given in Table 4. ERP P100 amplitude
demonstrated a significant effect of stimulus (F1,83=6.956,
p=0.01) and THC×cannabis use history interaction (F1,83=
Table 2 Summary of mean (SE) values of subjective high (immediately and 45min after smoking) and performance measures in the DATand SST for
heavy and occasional cannabis users
THC Placebo THC History THC×history
Heavy Occasional Heavy Occasional
Subjective high immediately after smoking (mm) 54.4 (7.9) 76.8 (8.1) 9.75 (3.9) 24.9 (7.4) 0.000 0.011 Ns
Subjective high 45 min after smoking (mm) 55.5 (8.8) 68.3 (7.7) 8.8 (3.6) 19.9 (7.5) 0.000 Ns Ns
DAT
Tracking error (mm) 17.5 (1.9) 18.5 (1.1) 17.0 (1.8) 13.5 (1.2) Ns Ns Ns
Control losses (#) 6.3 (2.4) 39.9 (16.5) 4.7 (2.7) 0.8 (0.4) 0.020 Ns 0.032
Hits (#) 72.3 (0.7) 67.0 (3.4) 72.5 (1.0) 74.5 (0.2) 0.030 Ns 0.041
RT (ms) 564.6 (18.3) 607.9 (23.8) 557.2 (19.0) 528.0 (10.3) 0.021 Ns 0.053
SST
Stop RT (ms) 769.0 (70.4) 717.8 (45.3) 756.7 (55.6) 657.7 (45.2) 0.029 Ns Ns
Accuracy (#) 90.8 (1.0) 81 (7.2) 90.8 (1.2) 91.8 (0.9) Ns Ns Ns
Ns not significant
Table 3 Mean (SD) serum concentrations (in nanograms per milliliter) of THC, THC-COOH, and OH-THC as a function of time after smoking
in occasional (THC condition only) and heavy users (THC and placebo condition)
Time after smoking (h)
Baseline 0.1 0.25 0.5 0.75 1.0
THC
Occasional (THC) 0.0 (0.0) 49.1 (24.9) 20.7 (9.3) 13.3 (5.3) 10.9 (4.4) 8.5 (3.3)
Heavy (THC) 3.4 (3.5) 120.9 (78.1) 47.4 (28.2) 30.3 (18.6) 22.6 (12.2) 19.0 (10.5)
Heavy (placebo) 2.9 (3.2) 3.0 (3.7) 3.0 (3.8) 2.9 (4.0) 2.9 (3.7) 3.0 (4.2)
THC-COOH
Occasional (THC) 1.6 (0.5) 12.0 (11.8) 10.5 (12.0) 9.5 (11.1) 8.5 (10.3) 7.5 (9.1)
Heavy (THC) 71.0 (79.0) 107.3 (95.8) 114.8 (96.2) 114.9 (92.3) 113.9 (92.6) 102.5 (85.4)
Heavy (placebo) 96.3 (177.5) 82.9 (135) 81.7 (156.5) 84.1 (136.9) 83.2 (139.1) 86.4 (142.8)
OH-THC
Occasional (THC) 0.0 (0.0) 6.6 (5.1) 5.7 (3.7) 4.7 (2.9) 4.0 (2.4) 3.3 (1.8)
Heavy (THC) 1.6 (1.7) 12.0 (10.7) 10.5 (8.5) 9.5 (7.8) 8.5 (6.7) 7.5 (5.7)
Heavy (placebo) 1.9 (3.1) 1.9 (3.3) 1.7 (2.8) 1.9 (3.1) 1.8 (2.8) 1.7 (2.9)
346 Psychopharmacology (2012) 220:341–3507.877, p=0.006). This interaction indicated that the occa-
sional users showed a decrease in P100 amplitude when
under the influence of THC, while in the heavy users, P100
increased when given THC compared to placebo (see
Figs. 1 and 2). Separate paired-sample t tests showed that
the decrease in P100 in occasional users after THC was
significantly different from placebo (t(19)=−2,74, p=
0.013), while the increase in heavy users was not (t(21)=
1,74, p=0.096). No effects were found for P100 latency in
the DAT.
P300 E R Pa n a l y s i si n c l u d e d1 1h e a v yu s e r sa n d1 0
occasional users in the THC condition and all subjects in
the placebo condition. P300 amplitude revealed significant
main effects of THC (F1,83=9.178, p=0.003), stimulus
(F1,83=53.520, p=0.000), and THC×stimulus interaction
(F1,83=6.364, p=0.014). No effect of cannabis use history
or interaction with cannabis use history was found. P300
amplitudes were largest for targets in the placebo condition
(see Fig. 3).
Stop signal task
Mean (SE) values for performance on the SST are given in
Table 2. The only behavioral SST measure that was
significantly affected by THC is the stop RT. THC
significantly increased stop RT (F1,44=5.123, p=0.029).
No effect of history of drug use or interaction was found on
the behavioral measures.
N200 No THC or cannabis use history effects were found on
theSSTfrontalN200.Amaineffectofstimulustypewasfound
on N200 amplitude (F4,15=56,491, p=0.000) and latency
(F4,15=683,429, p=0.000), showing the largest and slowest
N200 peaks for the stop trials with the longest delays. Mean
(SE) values of the ERPs from the SST are given in Table 4.
Correlations
The stop RT in the SST was positively correlated with THC
concentration measured before performance of the SST
Table 4 Summary of mean (SE) values of the ERPs in the DAT and SST for heavy and occasional cannabis users
THC Placebo THC History Stimulus THC×history THC×stimulus
Heavy Occasional Heavy Occasional
DAT
P100 amplitude (μV) Ns Ns 0.01 0.006 Ns
Distracters 2.54 (0.33) 2.96 (0.33) 2.34 (0.33) 3.72 (0.59)
Targets 3.9 (0.47) 3.43 (0.42) 2.67 (0.37) 5.47 (0.91)
P100 latency (ms) Ns Ns Ns Ns Ns
Distracters 145.6 (6.4) 138.8 (8.0) 138.7 (6.4) 145.7 (6.6)
Targets 139.8 (6.5) 139.3 (7.0) 138.2 (6.7) 147.6 (6.4)
P300 amplitude (μV) 0.003 Ns 0.000 Ns 0.014
Distracters 0.67 (0.4) 0.61 (0.5) 0.81 (0.4) 1.1 (0.3)
Targets 4.17 (1.1) 3.19 (0.4) 6.1 (1.1) 8.42 (1.7)
P300 latency (ms) Ns Ns Ns Ns Ns
Distracters 404.9 (15.0) 409.6 (23.5) 458.2 (25.3) 407.7 (22.0)
Targets 438.9 (25.2) 404.8 (11.7) 437.2 (13.5) 427.4 (20.5)
SST
N200 amplitude (μV) Ns Ns 0.000 Ns Ns
Go 0.88 (0.9) 2.09 (1.3) 0.06 (0.7) 2.50 (0.6)
NoGo50 −2.38 (1.2) −2.45 (0.8) −3.39 (0.5) −3.61 (0.5)
NoGo150 −1.14 (0.99) −0.79 (1.3) −0.40 (1.0) 1.81 (1.3)
NoGo250 −4.08 (1.4) −5.29 (0.9) −5.38 (1.7) −8.27 (1.3)
NoGo350 −8.58 (1.0) −8.91 (1.5) −7.98 (1.0) −10.31 (1.0)
N200 latency (ms) Ns Ns 0.000 Ns Ns
Go 223.0 (15.7) 208.2 (10.3) 227.4 (16.2) 207.6 (9.5)
NoGo50 250.2 (13.4) 250.5 (12.5) 253.3 (15.4) 229.7 (10)
NoGo150 334.8 (9.0) 366.6 (14.7) 359.7 (16.0) 354.9 (9.5)
NoGo250 462.8 (13.6) 499.6 (9.9) 493.83 (8.5) 505.6 (8.4)
NoGo350 579.9 (13.0) 594.4 (14.0) 582.7 (8.5) 589.2 (10.8)
Ns not significant
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0.38, p=0.011). Other correlations between ERP measures,
behavioral results, subjective high, or THC concentrations
were not significant.
Discussion
Previous studies have demonstrated that heavy cannabis
users develop tolerance for the impairing effects of
cannabis on cognitive performance. In the present study,
we used ERPs to differentiate the information processes
underlying the different performances of occasional and
heavy cannabis users in cognitive tasks. The results of this
study demonstrate that a drug use history by THC
interaction was only present in the early P100 component
which was measured during a DAT. In occasional users, the
P100 amplitude was found to be decreased in the THC
condition compared to the placebo condition. The P100 is
thought to represent early attentional selection (Taylor
2002) and has been found to be enhanced when distracters
are suppressed (Coull 1998). It could, therefore, be argued
that, in the present study, the occasional cannabis users are
less able to differentiate the targets from the distracters
when under the influence of THC, and hence, their P100 is
decreased. Since the heavy users do not demonstrate a
change in P100 amplitude after THC administration, this
could be an indication of tolerance to the effects of THC.
Cannabis also had an effect on the P300 of the DAT, i.e.,
amplitude was decreased after THC treatment. However, no
interaction was found with drug use history. It thus seems
that experienced users of THC were not tolerant to the
effect of THC on P300. Previous studies using ERPs have
also demonstrated that P300 is a robust measure of THC
intoxication. Ilan et al. (2004) studied ERPs while subjects
were in an intoxicated state. They showed that acute
administration of a low dose of cannabis (3.45% THC)
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Fig. 3 Grand average ERP showing P300 at Pz for targets in the DAT
of both groups of users together
Fig. 2 Mean (SE) P100 (Oz) amplitude during the DAT for heavy and
occasional users in the THC and placebo condition
Fig. 1 Grand average ERP showing P100 at Oz for targets in the
DAT. The upper panel shows ERPs of experienced users, while the
lower panel shows that of occasional users
348 Psychopharmacology (2012) 220:341–350impaired performance on a working memory task and an
episodic memory task, while at the same time amplitudes of
the related ERP components were decreased (N100, P200,
P300, and N400). Although this study only included casual
cannabis smokers (defined as using between once a month
and once a week during the last year), the authors did notice
that the degree of intoxication (measured by subjective
high) influenced the ERP, in that the most intoxicated
subject also showed the most decreased amplitudes.
Recently, Böcker et al. (2010) concluded that ERP
components related to selective attention were not influ-
enced by high doses of cannabis (29.3, 49.2, and 69.4 mg),
whereas amplitudes of components reflecting perceptual
processing as well as stimulus classification (P300) were
decreased. In this study, ERPs were measured 2 h after the
administration of THC in regular nondaily users. These
previousstudies,togetherwiththecurrentresults,demonstrate
that P300 is a particular sensitive measure of THC-induced
intoxication.
In the present study, no effects of THC for either of the
groups were found on the ERP component of the SST,
whereas the behavioral data did demonstrate increased stop
RT in both heavy and occasional users. It is possible that
the SST used is not well suited to elicit clear inhibition of
ERPs. For instance, it included 96 go and 96 stop signals,
which may be too little to elicit a clear and reliable N200.
In our previous study, we demonstrated that heavy users
only demonstrated impairment of impulse control in the
SST when THC concentrations were above 10 ng/ml in
serum. In the present study, we also demonstrated that THC
concentration was positively related with stop signal RT,
which measures impulse control.
The present data indicate that heavy cannabis users
did not show tolerance to THC effects on subjective
high. In addition, occasional cannabis users felt more
high after THC than heavy users, although THC serum
concentrations in heavy cannabis users were much higher
than those observed in occasional users. A single dose of
500 μg/kg THC produced a mean peak concentration of
120.9 ng/ml in heavy cannabis users and 49.1 ng/ml in
occasional users. Both groups were instructed to adhere
to the same smoking protocol. On average, occasional
and heavy users smoked 28 and 22 number of puffs of
the THC cigarette. Therefore, present differences in THC
concentrations seem to indicate that puff volume of
occasional and heavy cannabis users may have differed
and that heavy cannabis users needed higher THC
concentrations to achieve their desired high.
The current study appears to be the first to compare
acute effects of a high THC dose on ERPs in heavy and
occasional cannabis users. Our data confirm previous
studies in showing that P300 is decreased after cannabis
consumption, in occasional as well as heavy cannabis users.
In addition, we found that, at early attentional selection
processes, occasional cannabis users show a decreased
P100, whereas heavy users have developed tolerance.
These findings are in line with the behavioral data that
were demonstrated. THC significantly impaired performance
of occasional users on the DAT and the SST, whereas heavy
users were only impaired on the SST. Therefore, it can be
concludedthatheavycannabisusershavedevelopedtolerance
for some of the effects of THC and that this tolerance is also
demonstrated at the level of brain processing, as was shown
with the P100.
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